Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial

Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial

BackgroundThe appropriate age range for breast cancer screening remains a matter of debate. We aimed to estimate the effect of mammographic screening at ages 40–48 years on breast cancer mortality.MethodsWe did a randomised, controlled trial involving 23 breast screening units across Great Britain....

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Stephen W. Duffy, Daniel Vulkan, Howard Cuckle, Dharmishta Parmar, Shama Sheikh, Robert A. Smith, Andrew Evans, Oleg Blyuss, Louise Johns, Ian O. Ellis, Jonathan P. Myles, Peter Sasieni, Sue Moss
Hōputu:	Artigo
Reo:	Ingarihi
I whakaputaina:	2020
Urunga tuihono:	https://doi.org/10.1016/s1470-2045(20)30398-3 http://www.thelancet.com/article/S1470204520303983/pdf
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial
mā: Duffy, Stephen W, me ētahi atu.
I whakaputaina: (2020)

Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
mā: Duffy, Stephen, me ētahi atu.
I whakaputaina: (2020)

Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT
mā: Stephen W. Duffy, me ētahi atu.
I whakaputaina: (2020)

False-positive results in the randomised controlled trial of mammographic screening from age 40 (‘Age’ trial)
mā: Johns, Louise E, me ētahi atu.
I whakaputaina: (2010)

Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial
mā: Sue Moss, me ētahi atu.
I whakaputaina: (2015)

Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures
mā: Moss, S, me ētahi atu.
I whakaputaina: (2005)

Targeted encouragement of GP consultations for possible cancer symptoms: a randomised controlled trial
mā: Laake, Jean-Pierre, me ētahi atu.
I whakaputaina: (2020)

Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years
mā: Moss, S, me ētahi atu.
I whakaputaina: (2005)

Interim results from the Age Trial
mā: Moss, S, me ētahi atu.
I whakaputaina: (2004)

Malmö mammographic screening trial.
mā: Tabár, L., me ētahi atu.
I whakaputaina: (1989)

An ongoing case-control study to evaluate the NHS breast screening programme
mā: Massat, Nathalie J, me ētahi atu.
I whakaputaina: (2013)

An ongoing case–control study to evaluate the NHS Bowel Cancer Screening Programme
mā: Massat, Nathalie J, me ētahi atu.
I whakaputaina: (2014)

Trial of mammography in women under 50 is ethical
mā: Moss, Sue, me ētahi atu.
I whakaputaina: (1998)

Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35–39 at Increased Familial Risk of Breast Cancer()
mā: Evans, D.G., me ētahi atu.
I whakaputaina: (2019)

Should women 40 to 49 years of age be offered mammographic screening?
I whakaputaina: (2006)

Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time
mā: Duffy, Stephen W, me ētahi atu.
I whakaputaina: (2013)

Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time
mā: Stephen W. Duffy, me ētahi atu.
I whakaputaina: (2013)

Updated results of the Gothenburg Trial of Mammographic Screening
mā: Bjurstam, Nils G., me ētahi atu.
I whakaputaina: (2016)

Prospective estimation of rates of change in mammographic parenchymal patterns: influence of age and of hormone replacement (HRT) therapy
mā: Myles, JP, me ētahi atu.
I whakaputaina: (2004)

Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study
mā: Castanon, Alejandra, me ētahi atu.
I whakaputaina: (2020)

Rebuttal: Should women 40 to 49 years of age be offered mammographic screening?
I whakaputaina: (2006)

Assessing the amount of unscheduled screening (‘contamination’) in the control arm of the UK ‘Age’ Trial
mā: Kingston, Nicola, me ētahi atu.
I whakaputaina: (2010)

A case-control study to evaluate the impact of the breast screening programme on mortality in England
mā: Maroni, Roberta, me ētahi atu.
I whakaputaina: (2020)

Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
mā: Duffy, S W, me ētahi atu.
I whakaputaina: (2013)

The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density
mā: Ward, Sarah V., me ētahi atu.
I whakaputaina: (2022)

Overdiagnosis and overtreatment of breast cancer: Estimates of overdiagnosis from two trials of mammographic screening for breast cancer
mā: Duffy, Stephen W, me ētahi atu.
I whakaputaina: (2005)

Estimation of currently attainable benefit from mammographic screening of women aged 40-49 years
mā: Stephen A. Feig
I whakaputaina: (1995)

Overdiagnosis and overtreatment of breast cancer: Estimates of overdiagnosis from two trials of mammographic screening for breast cancer
mā: Stephen W. Duffy, me ētahi atu.
I whakaputaina: (2005)

Variation in Mammographic Breast Density by Time in Menstrual Cycle Among Women Aged 40-49 Years
mā: Emily White, me ētahi atu.
I whakaputaina: (1998)

Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.
mā: Andersson, I., me ētahi atu.
I whakaputaina: (1988)

Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial.
mā: Ingvar Andersson, me ētahi atu.
I whakaputaina: (1988)

Mammographic Breast Density and Urbanization: Interactions with BMI, Environmental, Lifestyle, and Other Patient Factors
mā: Perry, Nick, me ētahi atu.
I whakaputaina: (2020)

Malmö mammographic screening trial: Authors' reply
mā: Andersson, Ingvar, me ētahi atu.
I whakaputaina: (1989)

The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.
mā: Tabar, L, me ētahi atu.
I whakaputaina: (1989)

The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.
mā: Làszló Tabár, me ētahi atu.
I whakaputaina: (1989)

Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis
mā: Rebolj, Matejka, me ētahi atu.
I whakaputaina: (2018)

Pathology results from the UK Age Trial
mā: Ellis, IO, me ētahi atu.
I whakaputaina: (2004)

Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial
mā: Berthold, Frank, me ētahi atu.
I whakaputaina: (2021)

Opportunistic offering of self-sampling to non-attenders within the English cervical screening programme: a pragmatic, multicentre, implementation feasibility trial with randomly allocated cluster intervention start dates (YouScreen)
mā: Anita WW Lim, me ētahi atu.
I whakaputaina: (2024)

Faecal immunochemical testing in bowel cancer screening: Estimating outcomes for different diagnostic policies
mā: Li, Shuping J, me ētahi atu.
I whakaputaina: (2020)